<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913313</url>
  </required_header>
  <id_info>
    <org_study_id>CA020-002</org_study_id>
    <secondary_id>2016-002263-34</secondary_id>
    <nct_id>NCT02913313</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread</brief_title>
  <official_title>Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of experimental&#xD;
      medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both&#xD;
      nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">June 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median duration of response (mDOR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival rate (PFSR) at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator</measure>
    <time_frame>At 24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (mDOR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate (PFSR) at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>At 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval AUC(TAU)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentration at the end of a dosing interval (Ctau)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css-avg)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentrations (Ctrough)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Broad Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1A: Dose Escalation Monotherapy (BMS-986207)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: Dose Escalation Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Expansion Monotherapy (BMS-986207)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Expansion Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986207</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A: Dose Escalation Monotherapy (BMS-986207)</arm_group_label>
    <arm_group_label>Part 1B: Dose Escalation Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_label>Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <arm_group_label>Part 2A: Expansion Monotherapy (BMS-986207)</arm_group_label>
    <arm_group_label>Part 2B: Expansion Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_label>Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1B: Dose Escalation Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_label>Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <arm_group_label>Part 2B: Expansion Combination Therapy (BMS-986207 + nivolumab)</arm_group_label>
    <arm_group_label>Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <arm_group_label>Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must consent for pretreatment and on treatment tumor biopsy samples&#xD;
&#xD;
          -  For Part 1C tumor biopsies are optional&#xD;
&#xD;
          -  Nonsmall cell lung cancer (NSCLC) without prior treatment in the advanced or&#xD;
             metastatic setting (Part 2C)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Must have received, and progressed or been intolerant to, at least 1 standard&#xD;
             treatment regimen in the advanced or metastatic setting (Part 1A, 1B and 1C)&#xD;
&#xD;
          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic&#xD;
             tumor assessment performed within 28 days before randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary central nervous system (CNS) disease, or tumors with CNS metastases as the&#xD;
             only site of disease. Controlled brain metastases will be allowed to enroll&#xD;
&#xD;
          -  Other active malignancy requiring concurrent intervention&#xD;
&#xD;
          -  Uncontrolled/significant heart disease&#xD;
&#xD;
          -  History of chronic hepatitis [except for hepatocellular carcinoma (HCC)]&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, Site 0001</last_name>
      <phone>201-996-5823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emerson Lim, Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diwakar Davar, Site 0009</last_name>
      <phone>412-647-8762</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <state>Distrito Federal</state>
        <zip>1119</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Abdul Razak, Site 0007</last_name>
      <phone>41658648003883</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Recoleta</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Floresti/ Cluj</city>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Japan</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

